Rosetta Genomics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Rosetta Genomics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH15960D
  • |
  • Pages: 40
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Rosetta Genomics Ltd (RGL) is a developer of next generation diagnostic tests for personalized medicine. The company provides testing services such as cancer origin, next-gen, thyroid, lung, prostate, bladder, breast, kidney and specialty tests. It also develops tests for thyroid neoplasia, oncology, kidney rejection, Alzheimer's disease, therapeutics and CMV. The company offers RosettaGX platform on the cutting edge of molecular science and genomic testing technologies, with tests. It operates in Australia, New Zealand, Israel, Singapore, Canada, Greece, India, Saudi Arabia, Qatar, the UAE, Israel and Turkey. RGL is headquartered in Rehovot, Israel.

Rosetta Genomics Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Rosetta Genomics Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Rosetta Genomics Enters into Research Agreement with Sheba Medical Center 11

Rosetta Genomics Enters into Co-Development Agreement with Institute of Molecular Translational Medicine 12

Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center 13

Rosetta Genomics Enters into Co-Development Agreement with Weizmann Institute of Science 14

Rosetta Genomics And Marina Biotech Enter Into Agreement To Develop MicroRNA Diagnostics 15

Rosetta Genomics Enters Into Agreement With Ramot To Develop Nano-Carrier Delivery System To Treat Cancer 17

Licensing Agreements 18

Mirna Therapeutics Enters into Agreement with Rosetta Genomics 18

Equity Offering 19

Rosetta Genomics Raises USD2.7 Million in Public Offering of Units 19

Rosetta Genomics Raises USD5 Million in Second and Final Tranche of Private Placement of Shares 21

Rosetta Genomics Raises USD5 Million in First Tranche of Private Placement of Shares 22

Debt Offering 23

Rosetta Genomics Raises USD2 Million in Private Placement of Debentures and Warrants 23

Rosetta Genomics Raises USD1.3 Million in Second Tranche of Private Placement of Debentures and Warrants 24

Acquisition 25

Genoptix to Acquire Rosetta Genomics for USD9 Million 25

Pragmin Prognosis to Acquire Cynogen from Rosetta Genomics for USD3 Million 27

Rosetta Genomics Ltd-Key Competitors 28

Rosetta Genomics Ltd-Key Employees 29

Rosetta Genomics Ltd-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Strategy And Business Planning 31

Jul 06, 2017: Rosetta Genomics Expands Patent Portfolio in Canada, United States, and China 31

Financial Announcements 32

Oct 10, 2017: Rosetta Genomics Reports 2017 Second Quarter and Six Months Financial Results 32

Mar 30, 2017: Rosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results 35

Corporate Communications 37

Jul 18, 2018: Delisting of Securities of Rosetta Genomics, ConvergeOne Holdings, (Warrant Only), FC Global Realty, Concordia International, and Argos Therapeutics from The Nasdaq Stock Market 37

Apr 10, 2018: Rosetta Announces Resignation of Kenneth Berlin as President and CEO 38

Other Significant Developments 39

Sep 05, 2017: Rosetta Genomics to Reduce Operating and Other Expenses 39

Appendix 40

Methodology 40

About GlobalData 40

Contact Us 40

Disclaimer 40

List of Figures

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Rosetta Genomics Ltd, Medical Devices Deals, 2012 to YTD 2018 9

List of Tables

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Rosetta Genomics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Rosetta Genomics Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Rosetta Genomics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Rosetta Genomics Enters into Research Agreement with Sheba Medical Center 11

Rosetta Genomics Enters into Co-Development Agreement with Institute of Molecular Translational Medicine 12

Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center 13

Rosetta Genomics Enters into Co-Development Agreement with Weizmann Institute of Science 14

Rosetta Genomics And Marina Biotech Enter Into Agreement To Develop MicroRNA Diagnostics 15

Rosetta Genomics Enters Into Agreement With Ramot To Develop Nano-Carrier Delivery System To Treat Cancer 17

Mirna Therapeutics Enters into Agreement with Rosetta Genomics 18

Rosetta Genomics Raises USD2.7 Million in Public Offering of Units 19

Rosetta Genomics Raises USD5 Million in Second and Final Tranche of Private Placement of Shares 21

Rosetta Genomics Raises USD5 Million in First Tranche of Private Placement of Shares 22

Rosetta Genomics Raises USD2 Million in Private Placement of Debentures and Warrants 23

Rosetta Genomics Raises USD1.3 Million in Second Tranche of Private Placement of Debentures and Warrants 24

Genoptix to Acquire Rosetta Genomics for USD9 Million 25

Pragmin Prognosis to Acquire Cynogen from Rosetta Genomics for USD3 Million 27

Rosetta Genomics Ltd, Key Competitors 28

Rosetta Genomics Ltd, Key Employees 29

Rosetta Genomics Ltd, Other Locations 30

Rosetta Genomics Ltd, Subsidiaries 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Rosetta Genomics Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17500
Site License
USD 500 INR 35000
Corporate User License
USD 750 INR 52500

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com